Bodycote (LON:BOY) reported first-half core organic revenue growth of 9.6%, supported by strong demand in aerospace and defense, industrial gas turbines (IGT), medical and semiconductor-related markets, while continued automotive weakness weighed on performance. Chief Executive Officer Jim Fairbair

Bodycote’s updated fair value estimate has shifted slightly from £8.21 to £8.04, keeping the target close to earlier levels rather than signalling a big reset. This tweak sits alongside a research backdrop where targets cluster around £7.00 to £7.75 and ratings move between more optimistic and more cautious views on valuation and execution risk. Read on to see how to interpret these changes and keep track of how the Bodycote story evolves from here. Analyst Price Targets don't always capture...

Bodycote PLC (BYPLF) navigates a mixed fiscal year with strong aerospace gains and strategic initiatives, despite pressures in oil and gas sectors.

Bodycote (LON:BOY) management used its 2025 full-year results call to emphasize portfolio actions, improving second-half trading momentum, and a greater strategic tilt toward aerospace and other faster-growing markets. CEO Jim Fairbairn and CFO Ben Fidler said end markets were mixed through the year

The latest update to Bodycote’s narrative centres on a slightly higher fair value estimate of 8.07, supported by a marginally lower 8.99% discount rate and a trimmed 35.73% revenue growth assumption, all aimed at keeping expectations grounded while still backing the raised £1.00 price target. Bullish and bearish analysts both see these tweaks as a fine tuning of how risk and growth are being weighed, rather than a wholesale change in the story. Stay with this article to see how you can keep...

Bodycote’s story has just been refreshed, with the fair value estimate nudging up from £7.78 to £7.94 while JPMorgan trims its price target slightly from £6.10 to £6.00 and keeps a Neutral stance. Behind that small cut, the model now bakes in a big swing in revenue expectations, moving from an 8.45% decline to 38.12% growth. This helps explain why the central valuation output edges higher even as the official target comes down. Stay with this article to see how you can keep on top of these...

Bodycote’s updated narrative reflects a modestly higher fair value of £7.78 per share, even as revenue expectations swing from a previously assumed +13.3% increase to an estimated -8.4% decline. This shift captures a market split between analysts who see resilient medium term earnings power and those who remain cautious about near term demand and execution risks. Stay tuned to see how investors can track these evolving assumptions and keep on top of the shifting story around Bodycote’s...